

Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age

Adrian J. Lowe^{1,2,a} , Bianca Angelica^{1,a}, John Su^{2,3,4}, Caroline J. Lodge^{1,2}, David J. Hill², Bircan Erbas⁵, Catherine M. Bennett^{1,6}, Lyle C. Gurrin¹, Christine Axelrad², Michael J. Abramson⁷, Katrina J. Allen^{2,4} & Shyamali C. Dharmage^{1,2}

¹Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Vic., Australia; ²Murdoch Childrens Research Institute, Melbourne, Vic., Australia; ³Monash University, Eastern Health Melbourne, Vic., Australia; ⁴Department of Paediatrics, University of Melbourne, Melbourne, Vic., Australia; ⁵School of Psychology and Public Health, La Trobe University, Melbourne, Vic., Australia; ⁶Centre for Population Health Research, Deakin University, Melbourne, Vic., Australia; ⁷Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Vic., Australia

To cite this article: Lowe AJ, Angelica B, Su J, Lodge CJ, Hill DJ, Erbas B, Bennett CM, Gurrin LC, Axelrad C, Abramson MJ, Allen KJ, Dharmage S. Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age. *Pediatr Allergy Immunol* 2017; **28**: 384–390.

Keywords

eczema; asthma; allergic rhinitis; epidemiology; risk factors; natural history

Correspondence

Adrian Lowe, Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, 3010 Melbourne, Vic., Australia
Tel.: +61 3 8344 0878
Fax: +61 3 9349 5815
E-mail: lowea@unimelb.edu.au

^aEqual first author.

Accepted for publication 13 March 2017

DOI:10.1111/pai.12714

Abstract

Background: Few studies have simultaneously addressed the importance of age of onset and persistence of eczema for the subsequent development of asthma and hay fever, particularly into early adulthood.

Methods: A high-risk birth cohort was recruited comprising 620 infants, who were then followed up frequently until 2 years of age, annually from age 3 to 7, then at 12 and 18 years, to document any episodes of eczema, current asthma, and hay fever. The generalized estimation equation technique was used to examine asthma and hay fever outcomes at 6 (n = 325), 12 (n = 248) and 18 (n = 240) years, when there was consistency of associations across the follow-ups.

Results: Very early-onset persistent (onset <6 months, still present from 2 to 5 years) eczema was related to current asthma (adjusted OR = 3.2 [95% CI = 1.7–6.1]), as was very early-onset remitting eczema (onset <6 months but not present from 2–5 years, OR = 2.7, 95% CI = 1.0–7.2) and early-onset persistent eczema (onset from 6–24 months, OR = 2.3, 95% CI = 1.2–4.7). Late-onset eczema (commenced from 2–5 years) was associated with increased risk of asthma at 12 years (OR = 3.0, 95% CI = 1.1–8.2) but not at age 6 years. Only very early-onset persistent eczema was associated with increased risk of hay fever (aOR = 2.4, 95% CI = 1.4–4.1).

Conclusion and clinical relevance: Eczema which commences in early infancy and persists into toddler years is strongly associated with asthma, and to a lesser extent hay fever, in high-risk children. If these associations are causal, prevention of early-life eczema might reduce the risk of respiratory allergy.

Eczema is an increasingly prevalent skin condition (1), that frequently, but not always, starts early in life and remits before adolescence (2). Children with eczema tend to develop food allergy, asthma, and allergic rhinitis at later ages, an aspect of the atopic march hypothesis (3), which suggests a possible

causal role of eczema in the development of allergic airways disease.

There is emerging evidence that the development of early-life eczema may be prevented by regular use of emollients (4, 5). While early-life interventions, such as daily emollient application, may be feasible in the first months of life, it is likely that it will not be possible to continue such preventive treatments indefinitely. Better understanding of the long-term prognosis of early-life eczema, based on age of onset and persistence, and its

Abbreviations

aOR, adjusted odds ratio; MACS, Melbourne Atopy Cohort Study; OR, odds ratio; SPT, skin prick test.

relationship with allergic airways disease, may help inform optimal duration of early-life preventive interventions.

Relatively few studies have examined the differential associations between age of onset and persistence of eczema and later development of asthma and allergic rhinitis (6–8). We have previously demonstrated that early-onset (particularly under 6 months) and more severe eczema is associated with increased risk of asthma at age 6–7 years, especially in boys (9). Here, we extend on our previous work by using the same prospective birth cohort to examine the role of age of eczema onset and persistence of eczema symptoms in the development of hay fever and asthma up to age 18 years.

Methods

Study population

The Melbourne Atopy Cohort Study (MACS) (10, 11) is a prospective birth cohort of 620 babies recruited prenatally in Melbourne, Australia, between 1990 and 1994, on the basis of eczema, hay fever, asthma, or severe food allergy in at least one first-degree relative, and followed to 18 years of age. The study started as a randomized controlled trial of three infant formulas at weaning (10). The project was approved by the Human Research Ethics Committee of the Mercy Hospital for Women. All mothers gave written informed consent.

Data collection

Baseline information was collected with questionnaires during pregnancy. Following birth, standardized telephone questionnaires were administered by an allergy-trained nurse 18 times in first 2 years, annually up to 7 years, and at 12 and 18 years. Each survey documented any episodes of illness since the previous interview.

Skin prick testing (SPT) was performed at 6, 12, 24 months, and 12 and 18 years, according to a standard technique (12) with the following allergens: cow's milk, egg white, peanut, house dust mite, rye grass, and cat dander (Bayer, Spokane, WA, USA). A positive (histamine 1 mg/ml) control was used. Wheals were measured and recorded at 15–20 min.

Definitions

Eczema in the first 2 years of life was defined as parental report of either a doctor diagnosis of eczema or any rash (excluding scalp or nappy rashes) which was treated with topical steroid (13). Eczema from age three to 12 was defined as parental report of one or more episodes of eczema or rash treated with topical steroid or episodes of eczema which required a visit to the doctor, in the past 12 months.

Early-onset eczema was defined as eczema which commenced before age 2 years, and very early-onset eczema was defined as eczema that commenced in the first 6 months.

'Early-onset persistent eczema' was defined as early-onset eczema which was still present between ages 2 and 5, while 'early-onset remitting eczema' defined eczema which only manifested in the first 2 years, but not between ages 2 and 5.

'Late-onset eczema' described eczema first arising between ages two and seven. From ages 6–18 years, asthma and hay fever were defined as parental report of one or more episodes of asthma and hay fever in the past 12 months, respectively. A skin prick test of 2 mm or greater in the first 2 years of life was defined as positive, while a 3-mm cut point was used at 12 and 18 years.

Statistical analysis

Logistic regression models were used to examine the associations between age of eczema onset and persistence up to 5 years of age and the risk of eczema, asthma, and hay fever and sensitization to food and inhalant allergens. Generalized estimating equations (GEE) were used to accommodate repeated measurements for these outcomes. To test whether these associations changed over time, interactions between age of onset and persistence of eczema symptoms and age of follow-up were tested. If there was possible evidence that the associations varied over time ($p < 0.1$ for interaction with time), a pooled result was not reported. Regression models were adjusted for both *a priori* confounders (weight at 4 weeks, gender, parental history of atopic conditions, duration of breastfeeding in weeks, and group of randomization) and the following potential confounders: number of siblings, carpets in home environment, pet ownership, parental smoking during pregnancy, and socio-economic status if they caused a 10% or greater change in the odds ratio were included in the final multiple regression models. Stata release 13.0 (College Station, Texas) was used for all statistical analyses. Results are presented as OR with 95% confidence intervals.

Results

Study population

Of the 620 infants recruited, 92.7% were followed up at age two, 79.8% were assessed at least once at 6 or 7 years, and 58.9% and 67.4% at the 12- and 18-year follow-up, respectively (Fig. 1). Children of parents with proxy markers for lower socio-economic status were more likely to be lost to follow-up (11). Early signs of atopy or eczema in the child were not associated with loss to follow-up (11). Participants who could not be included in the analysis due to missing data, but who had outcome data at the follow-up periods, had similar prevalences of allergic disease as those who were included (Table S1).

Prevalence of eczema

Of the 325 children with complete data up to 7 years of age, by 6 months of life, 21.5% ($n = 70$) had developed eczema, while 47.4% ($n = 154$) had developed eczema by age 2 years. The prevalence of current eczema declined with age and was 21.3% at age of 18 years. Of the children who had not developed eczema by 2 years, 34.5% (59/171) developed late-onset eczema between 2 and 7 years, but relatively few children first




Figure 1 Follow-up rate of participants in the first 18 years.

developed symptoms between 7 and 12 years (8.4%, 7/83) or from 12 to 18 years (6.7%, 4/60).

Risk of current eczema

Children with a history of eczema within the first 5 years had an increased risk of current eczema at 6, 12, and 18 years, but the strongest association was for children who had eczema that commenced by 1 year (Table 1). The strength of these associations was greatest at 6/7 years, and declined by the 18-year follow-up (*p* values for interaction <0.05), so pooled estimates were not reported.

Risk of asthma

Very early-onset persistent eczema was strongly associated with asthma (aOR = 3.2, 95% CI = 1.7–6.1, Table 2). This

association was observed even when children who had early wheeze (35.3%, 203/575) were excluded (aOR = 3.8, 95% CI = 1.6–9.3). Early-onset (6–24 months) persistent eczema was also associated with an increased risk of asthma. There was a trend toward increased risk of asthma for early-onset remitting eczema and asthma at each time point, and the pooled estimate indicated an increased risk (OR = 2.7, 1.0–7.2). Late-onset eczema was associated with an increased risk only at 12 years of age (*p* for interaction = 0.01, Table 2). More years of having eczema was associated with an increased risk of asthma at all ages (*p* for trend <0.01 at all ages).

At ages 6 and 7, the association between early-onset persistent eczema and asthma was seen in boys (aOR = 6.9; 95% CI = 2.7–17.9) but not in girls (aOR = 1.7; 95% CI = 0.55–5.3; *p* for interaction = 0.05) (9). This gender difference was not seen at the 12- or 18-year follow-ups (all *p* for interactions >0.2).

Table 1 Risk of eczema by age of eczema onset

	6–7 year outcome* (n = 325)		12 year outcome (n = 241) [†]		18 year outcome (n = 240)		
	% With eczema* (n/N)	Adjusted OR [§] (95% CI)	% with eczema (n/N)	Adjusted OR [§] (95% CI)	% with eczema (n/N)	Adjusted OR [§] (95% CI)	Repeated measures aOR*
0–6 months	50.0 (35/70)	9.5 (4.5–19.9)	39.5 (17/43)	6.4 (2.4–17.5)	35.6% (16/45)	5.7 (2.2–15.0)	[¶]
6–12 months	53.1 (26/49)	10.1 (4.5–22.4)	41.5 (17/41)	7.5 (2.7–21.2)	29.3% (12/41)	4.0 (1.5–11.2)	[¶]
12–24 months	40.0 (14/35)	5.6 (2.3–14.0)	35.7 (10/28)	5.7 (1.8–17.7)	34.5% (10/29)	4.3 (1.4–13.2)	5.7 (2.7–11.9)
2–5 years	42.6 (20/47)	5.5 (2.4–12.8)	18.9 (7/37)	2.1 (0.6–6.8)	10.0% (3/30)	0.8 (0.1–3.9)	[¶]
No eczema ≤5 y	9.7 (12/124)	1	9.8 (9/92)	1	10.5% (10/95)	1	1

*Odds ratios (OR) were estimated using repeated measures (generalized estimation equation).

[†]Seven participants had missing eczema outcome data at age 12 years.

[§]Adjusted for weight at 4 weeks, gender, parental history of eczema, duration of breastfeeding and randomization.

[¶]Indicates one or more significant difference in associations between the follow-up periods, so no pooled estimate is provided.

Table 2 Risk of *asthma* at age 6 and 7, 12 and 18 years by age of onset and persistence of eczema symptoms

Pattern of eczema	6–7 years (n = 325)*		12 years (n = 240) [†]		18 years (n = 240)		Repeated measures aOR*
	% with asthma (n/N)	aOR [‡] (95% CI)	% with asthma (n/N)	aOR [‡] (95% CI)	% with asthma (n/N)	aOR [‡] (95% CI)	
0–6 m persistent	47.1 (24/51)	3.2 (1.6–6.5)	48.5 (16/33)	6.5 (2.5–17.1)	28.6% (10/35)	2.9 (1.0–8.1)	3.2 (1.7–6.1)
0–6 m remitting	31.6 (6/19)	2.0 (0.7–5.8)	33.3 (3/9)	5.8 (1.0–33.3)	27.3% (3/11)	4.0 (0.8–19.3)	2.7 (1.0–7.2)
6–24 m persistent	32.0 (16/50)	1.9 (0.9–4.2)	32.5 (13/40)	3.7 (1.3–10.1)	22.7% (10/44)	3.1 (1.1–8.5)	2.3 (1.2–4.7)
6–24 m remitting	23.5 (8/34)	1.4 (0.5–3.6)	20.7 (6/29)	2.0 (0.6–7.0)	19.2% (5/26)	1.7 (0.4–6.5)	1.5 (0.6–3.6)
Late-onset	29.8 (14/47)	1.4 (0.6–3.1)	32.4 (12/37)	3.0 (1.1–8.2)	33.3% (10/30)	2.8 (1.0–8.4)	¶
No eczema [¶]	21.8 (27/124)	1	13.0 (12/92)	1	10.6% (10/94)	1	1

*Odds ratios (OR) estimated using repeated measures (generalized estimation equation) for any episode of asthma in the previous 12 months at each follow-up point.

[†]Eight participants had missing asthma outcome data at age 12 years.

[‡]Adjusted for weight at 4 weeks, gender, parental history of asthma, duration of breastfeeding and randomization.

[¶]Indicates one or more significant difference in associations between the follow-up periods, so no pooled estimate is provided.

Bolded values indicate $p < 0.05$

Risk of hay fever

Very early-onset persistent eczema was related to increased risk of hay fever (Table 3). There was no evidence of an association between eczema that commenced later, regardless of persistence.

Risk of sensitization

Very early-onset persistent eczema was associated with an increased risk of food sensitization at all time points (Table 4). These associations varied over time and were particularly strong at 12 months and 12 years. The only other eczema group to be associated with food sensitization and then only at 12 years was eczema that commenced from 6 to 24 months and was persistent (aOR = 4.3, 95% CI = 1.4–12.4). Very early-onset persistent eczema was again associated with increased risk of inhalant sensitization at all time points (repeated measures aOR = 2.4, 95% CI = 2.2–5.2, Table 5). Both late-onset eczema and early-onset persistent eczema were associated with increased risk of inhalant sensitization at 18 years only.

Discussion

In this birth cohort of children with family history of allergic diseases followed prospectively until 18 years, very early-onset (<6 months) *persistent* eczema (up to age 5) was associated with increased risk of both asthma and hay fever and sensitization. The association between early-onset persistent eczema and increased risk of asthma, and hay fever, was still evident even when children with early-onset wheeze were excluded. This study is the first to clearly demonstrate that the strongest and most consistent associations between eczema and allergic airways disease are for the very early-onset (<6 months) and persistent eczema, highlighting this as a period where interventions to prevent the atopic march may be effective.

Broadly, the results from this study are comparable to previously published findings. Direct comparisons between studies are difficult due to differences in definitions used when defining 'early-onset' eczema. Less than 6 months (9), 1 year (6), 2 years (8, 14), and 3 years (7) have been used in various papers. Consistent patterns of our findings with these studies

Table 3 Risk of *hay fever* at age 6 & 7, 12 and 18 years by age of onset and persistence of eczema symptoms

Pattern of eczema*	6–7 years (n = 325)*		12 years (n = 241) [†]		18 years (n = 239) [†]		Repeated measures aOR*
	% With hay fever (n/N)	aOR [‡] (95% CI)	% With hay fever (n/N)	aOR [‡] (95% CI)	% With hay fever (n/N)	aOR [‡] (95% CI)	
0–6 m persistent	41.2 (21/51)	2.5 (1.2–5.2)	64.7 (22/34)	5.5 (2.2–13.3)	61.8% (21/35)	2.7 (1.2–6.4)	2.4 (1.4–4.1)
0–6 m remitting	26.3 (5/19)	1.3 (0.4–4.3)	33.3 (3/9)	2.4 (0.5–13.1)	54.6% (6/11)	1.6 (0.4–6.3)	1.4 (0.6–3.3)
6–24 m persistent	26.0 (13/50)	1.6 (0.7–3.7)	37.5 (15/40)	2.0 (0.8–4.7)	36.4% (16/44)	0.8 (0.4–1.8)	1.4 (0.8–2.5)
6–24 m remitting	29.4 (10/34)	1.2 (0.5–3.3)	27.6 (8/29)	1.3 (0.5–3.7)	40.0% (10/25)	1.3 (0.5–3.4)	1.3 (0.7–2.6)
Late-onset	25.5 (12/47)	1.4 (0.6–3.3)	43.2 (16/37)	2.3 (1.0–5.5)	33.3% (10/30)	0.8 (0.3–1.9)	1.4 (0.8–2.6)
No eczema	18.6 (23/124)	1	26.1 (24/92)	1	36.8% (35/94)	1	1

*Odds ratios (OR) estimated using repeated measures (generalized estimation equation) for any episode of hay fever in the previous 12 months at each follow-up point.

[†]Seven participants had missing hay fever outcome data at age 12 years and 1 participant had missing data at 18 years.

[‡]Adjusted for weight at 4 weeks, gender, and parental history of hay fever.

Bolded values indicate $p < 0.05$

Table 4 Risk of food sensitization* at age 6, 12 and 24 months and, 12 and 18 years by age of onset and persistence of eczema symptoms

Pattern of eczema	6 months (n = 313)		12 months (n = 287)		24 months (n = 243)		18 years (n = 223)		Repeated measures aOR†
	% (n/N)	aOR‡ (95% CI)	% (n/N)	aOR‡ (95% CI)	% (n/N)	aOR‡ (95% CI)	% (n/N)	aOR‡ (95% CI)	
0–6 m persistent	38.0% (19/50)	3.3 (1.5–7.0)	59.2% (29/49)	7.1 (3.3–15.2)	37.8% (17/45)	3.8 (1.6–8.7)	25.7% (9/35)	5.2 (1.5–17.9)	¶
0–6 m remitting	27.8% (5/18)	2.0 (0.6–6.6)	26.3% (5/19)	1.8 (0.5–5.9)	20.0% (3/15)	1.5 (0.4–6.6)	10.0% (1/10)	1.9 (0.2–19.0)	1.9 (0.8–4.7)
6–24 m persistent	14.3% (7/49)	0.8 (0.3–2.1)	26.0% (13/50)	1.6 (0.7–3.8)	23.9% (11/46)	2.1 (0.8–5.4)	12.5% (5/40)	2.1 (0.5–8.7)	¶
6–24 m remitting	19.4% (6/31)	1.2 (0.4–3.7)	22.6% (7/31)	1.9 (0.7–5.1)	16.1% (5/31)	1.5 (0.5–4.8)	4.2% (1/24)	0.8 (0.1–7.9)	1.5 (0.7–3.3)
Late-onset	13.0% (6/46)	0.9 (0.3–2.3)	6.5% (3/46)	0.4 (0.1–1.3)	10.3% (4/39)	0.8 (0.2–2.5)	15.8% (6/38)	2.1 (0.7–7.0)	¶
No eczema	16.8% (20/119)	1	16.9% (20/118)	1	15.3% (17/111)	1	9.8% (9/92)	1	1

*Food sensitization: sensitization to one or more of milk, egg or peanut.

†Odds ratios (OR) estimated using repeated measures (generalized estimation equation).

‡Adjusted for weight at 4 weeks, gender, parental history of eczema, duration of breastfeeding and randomization.

¶Indicates one or more significant difference in associations between the follow-up periods, so no pooled estimate is provided.

Bolded values indicate $p < 0.05$ **Table 5** Risk of inhalant sensitization* at age 6, 12 and 24 months and, 12 and 18 years by age of onset and persistence of eczema symptoms

Pattern of eczema	6 months (n = 313)		12 months (n = 287)		24 months (n = 243)		18 years (n = 225)		Repeated measures aOR*
	% (n/N)	aOR† (95% CI)	% (n/N)	aOR† (95% CI)	% (n/N)	aOR† (95% CI)	% (n/N)	aOR† (95% CI)	
0–6 m persistent	20.0% (10/50)	3.9 (1.4–11.0)	44.9% (22/49)	6.3 (2.8–14.3)	53.3% (24/45)	4.0 (1.9–8.6)	85.3% (29/34)	5.0 (2.0–12.6)	3.4 (2.2–5.2)
0–6 m remitting	0.0% (0/18)	–	31.6% (6/19)	3.1 (0.9–9.9)	46.7% (7/15)	3.1 (1.0–9.9)	44.4% (4/9)	2.2 (0.4–11.3)	1.7 (0.8–3.4)
6–24 m persistent	4.1% (2/49)	0.6 (0.1–3.2)	14.0% (7/50)	1.2 (0.5–3.3)	26.1% (12/46)	1.3 (0.6–3.0)	57.5% (23/40)	1.9 (0.8–4.3)	¶
6–24 m remitting	6.5% (2/31)	1.1 (0.2–5.8)	12.9% (4/31)	1.2 (0.3–3.9)	25.8% (8/31)	1.4 (0.6–3.8)	50.0% (15/30)	1.6 (0.6–3.9)	1.5 (0.9–2.6)
Late-onset	4.3% (2/46)	0.8 (0.2–3.8)	15.2% (7/46)	1.3 (0.5–3.5)	23.1% (9/39)	0.9 (0.4–2.2)	57.9% (22/38)	1.9 (0.8–4.1)	¶
No eczema	6.7% (8/119)	1	12.7% (15/118)	1	23.4% (26/111)	1	41.3% (38/92)	1	1

*Odds ratios (OR) estimated using repeated measures (generalized estimation equation).

†Adjusted for weight at 4 weeks, gender, parental history of eczema, duration of breastfeeding and randomization.

‡Inhalant sensitization: sensitization to one or more of dust mite, rye grass or cat dander.

¶Indicates one or more significant difference in associations between the follow-up periods, so no pooled estimate is provided.

Bolded values indicate $p < 0.05$

are that persistent eczema and earlier onset eczema are more strongly related to asthma, allergic rhinitis, and allergic sensitization than remitting and late-onset eczema. Some studies have failed to show an association between late-onset eczema and increased risk of asthma or allergic rhinitis (8, 14) up to the ages of 7 and 12 years, while a very large, data linkage, study found an increased risk of both conditions with late-onset eczema. Interestingly, we found that late-onset eczema was not related to atopy, asthma, or allergic rhinitis up to 7 years of age, but that there was evidence of increased risk of asthma at 12 years and inhalant sensitization at 18 years. When coupled with our observation that greater years of symptoms of eczema is associated with increased risk of asthma and allergic rhinitis, this observation may indicate that there is a cumulative effect of eczema and that even late-onset eczema, if persistent, is associated with increased risk of these conditions with increasing age.

The mechanism of these associations has not been clearly elucidated and may be due to shared genetic or environmental risk factors, or due to a causal mechanism. At this time, there are few known shared environmental risk factors for the development of both eczema and allergic airways disease, except possibly for early-life exposure to pets (15, 16) and indoor mold (17). The strongest evidence for a shared genetic risk factor comes from filaggrin (FLG) null mutations (18), which have been shown to be strongly associated with early-onset (19) and persistent eczema (20), and risk of asthma, but only in children who have also developed eczema (21). Sensitization to inhalant allergens is an important risk factor for asthma (22) and allergic rhinitis (23), and early-onset eczema can predict new onset sensitization (24, 25). It is possible that the association between early-onset eczema and later respiratory allergic disease may be due to an increased risk of aero-allergen sensitization, mediated by impaired skin barrier function. Alternatively, chronic eczema lesions may express thymic stromal lymphopoietin (TSLP), and other pro-inflammatory mediators, which then increases the risk of developing allergic inflammation and sensitization in the lungs (26). This is consistent with our observation that greater numbers of years with eczema symptoms were associated with increased risk of both asthma and hay fever.

Previously some authors have argued that the association between early-life eczema and childhood asthma is due to confounding by sensitization and that eczema is not a true independent risk factor for asthma (27). While we had data on allergic sensitization in this cohort, for many participants, it was unclear whether sensitization or eczema came first, so we did not have sufficient sample size to tease out independent effects of eczema and sensitization. We recommend investigation of this issue in future studies.

Key strengths of this study include its prospective design, regular assessments of eczema from birth to age 18, multiple measurements of sensitization to common allergens, and assessments up to 18 years, when the nature of wheeze and rhinitis is much easier to determine than in early life. The prospective design of this study reduces possible recall bias and also allowed for an analysis of the persistence or remission of symptoms.

The definition of eczema used within this study is a limitation. Eczema in the first 2 years of life was defined as a doctor-diagnosed eczema or parental report of rash (excluding those on the scalp or nappy area) treated with topical steroid. This definition of eczema has been validated, and shown reasonable sensitivity (85%) and specificity (81%) (28). Another possible weakness was the minor variations between questionnaires administered at different follow-ups, resulting in a very slight difference in the definition of eczema before and after age two.

A further limitation of these results is that only 38.7% of the cohort had complete follow-up at all time points. This restriction allowed us to define age of onset and persistence of eczema. Although this reduced our statistical power to observe associations, it appears unlikely to have introduced bias. We elected to report results as odds ratios, which are larger than risk ratios when the outcome is common as seen in this study, for computational reasons. Finally, these results may not be applicable children without a family history of allergic disease.

Observations from the current study suggest that appropriate interventions in early life could potentially reduce the progression of eczema to asthma and hay fever, especially in children with very early-onset disease. Restoration of skin barrier function in infants and patients with eczema, before sensitization occurs, may be beneficial. Evidence from recent small-scale trials suggests that such preventive strategies may reduce the incidence of early-onset eczema (4, 5). Hence, further work is urgently required to confirm whether this may also lead to reduce rates of sensitization and allergic airways disease. Proactive management of early-onset eczema, including skin hydration and regular use of emollients, antiseptics, and topical anti-inflammatory agents, might be practical secondary preventive measures to reduce the risk of the atopic march progressing.

Conclusions

Our findings show that very early-onset persistent eczema is strongly associated with asthma and hay fever later in life in children with a family history of allergic disease. If these associations are causal, effective intervention in early-life eczema may reduce the risk of asthma and hay fever. The first 6 months of life appears to be the most important period where eczema prevention may reduce risk of asthma and allergic rhinitis.

Acknowledgments

We thank Dr John Thorburn for assistance in patient recruitment and administrative assistance and the Mercy Maternity Hospital Department of Obstetrics for participant recruitment and Dr Cliff Hosking for study leadership from 1989 to 2005. We thank Anne Balloch for assistance with data management and Rida Khalafzai, Carlie Dunford, and Jeeva Sanjeevan for coordinating the 18-year follow-up. We acknowledge the following investigators of the 18-year follow-up: Paul Thomas, Melanie C Matheson, Sharon Goldfeld, Vijaya Sundararajan, Christopher Barton, John Hopper, Cecilie Svanes. Finally, we thank all of the MACS children and parents for their participation and ongoing support for this study.

Declaration of all sources of funding

Nestec Ltd, a subsidiary of Nestle Australia, provided staff funding for the first 6 years of the study, Asthma Foundation of Victoria supported the 12-year follow-up, while the National Health and Medical Research Council of Australia (NHMRC) funded the 18-year follow-up (APP454856). A.J.L., C. J. L., K.J.A., and S.C.D. are supported by the National Health and Medical Research Council of Australia.

Conflict of interest statement

A Lowe declares he has received in kind research support (donation of EpiCeram emollient) from PuraCap pharmaceuticals for use in an eczema prevention trial (see ACTRN12613000472774). All other authors declare they have no conflicts of interest in relation to this manuscript.

References

- Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006; **368**: 733–43.
- Bieber T. Atopic dermatitis. *N Engl J Med* 2008; **358**: 1483–94.
- Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. *Allergy* 2014; **69**: 17–27.
- Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J Allergy Clin Immunol* 2014; **134**: 818–23.
- Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. *J Allergy Clin Immunol* 2014; **134**: 824–30 e6.
- von Kobyletzki LB, Bornhag CG, Hasselgren M, Larsson M, Lindstrom CB, Svensson A. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. *BMC Dermatol* 2012; **12**: 11.
- Shen CY, Lin MC, Lin HK, Lin CH, Fu LS, Fu YC. The natural course of eczema from birth to age 7 years and the association with asthma and allergic rhinitis: a population-based birth cohort study. *Allergy Asthma Proc* 2013; **34**: 78–83.
- Carlsten C, Dimich-Ward H, Ferguson A, et al. Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors. *Ann Allergy Asthma Immunol* 2013; **110**: 24–8.
- Lowe AJ, Carlin JB, Bennett CM, et al. Do boys do the atopic march while girls dawdle? *J Allergy Clin Immunol*. 2008; **121**: 1190–5.
- Lowe AJ, Hosking CS, Bennett CM, et al. Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic disease in high-risk children: a randomized controlled trial. *J Allergy Clin Immunol*. 2011; **128**: 360–5.
- Lowe AJ, Lodge CJ, Allen KJ, et al. Cohort profile: Melbourne Atopy Cohort study (MACS). *Int J Epidemiol*. 2016; pii: dyw011. [Epub ahead of print].
- Aas K, Belin L. Standardization of diagnostic work in allergy. *Int Arch Allergy Appl Immunol* 1973; **45**: 57–60.
- Lowe AJ, Carlin JB, Bennett CM, et al. Atopic disease and breastfeeding - cause or consequence? *J Allergy Clin Immunol* 2006; **117**: 682–7.
- Kjellman B, Hattveig G. Allergy in early and late onset of atopic dermatitis. *Acta Paediatr* 1994; **83**: 229–31.
- Foisy M, Boyle RJ, Chalmers JR, Simpson EL, Williams HC. Overview of reviews the prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews. *Evid Based Child Health* 2011; **6**: 1322–39.
- Lodge CJ, Allen KJ, Lowe AJ, et al. Perinatal cat and dog exposure and the risk of asthma and allergy in the urban environment: a systematic review of longitudinal studies. *Clin Dev Immunol* 2012; **2012**: 176484.
- Mendell MJ, Mirer AG, Cheung K, Tong M, Douwes J. Respiratory and allergic health effects of dampness, mold, and dampness-related agents: a review of the epidemiologic evidence *Environ Health Perspect*. 2011; **119**: 748–56.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 2006; **38**: 441–6.
- Stemmler S, Parwez Q, Petrasch-Parwez E, Epplen JT, Hoffjan S. Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. *J Invest Dermatol* 2007; **127**: 722–4.
- Brown SJ, Sandilands A, Zhao Y, et al. Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. *J Invest Dermatol* 2008; **128**: 1591–4.
- van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. *BMJ* 2009; **339**: b2433.
- Lodge CJ, Lowe AJ, Gurrin LC, et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. *J Allergy Clin Immunol* 2011; **128**: 782–8 e9.
- Schafer T, Wolke G, Ring J, Wichmann HE, Heinrich J. Allergic sensitization to cat in childhood as major predictor of incident respiratory allergy in young adults. *Allergy* 2007; **62**: 1282–7.
- Lowe AJ, Abramson MJ, Hosking CS, et al. The temporal sequence of allergic sensitization and onset of infantile eczema. *Clin Exp Allergy* 2007; **37**: 536–42.
- Almqvist C, Li Q, Britton WJ, et al. Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'. *Clin Exp Allergy* 2007; **37**: 1296–302.
- Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. *PLoS Biol*. 2009; **7**: e1000067.
- Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004; **113**: 925–31.
- Lowe A, Boyle R, Su J, et al. Validation of definitions of eczema in infancy used in research. *Intern Med J* 2010; **40**: 13.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Prevalence of eczema, asthma and hay-fever in participants included and excluded from the analysis.

Supplementary table 1. Prevalence of eczema, asthma and hay-fever in participants included and excluded from the analysis.

Follow-up	Eczema			Asthma			Hay-fever		
	Included	Excluded	P	Included	Excluded	P	Included	Excluded	P
6/7 years	32.9% (107/325)	29.4% (50/170)	0.43	29.2% (95/325)	31.2% (53/170)	0.65	25.2% (82/325)	18.9% (32/169)	0.11
12 years	24.9% (60/241)	21.9% (26/119)	0.52	25.8 % (62/240)	18.5% (22/119)	0.12	36.5% (88/241)	38.7% (46/119)	0.70
18 years	21.3% (51/240)	21.2% (38/179)	1.0	20.0% (48/240)	16.9% (30/178)	0.41	41.0% (98/239)	42.1% (77/183)	0.83